BofA resumed coverage of Select Medical (SEM) with a Buy rating and $42 price target and updated the firm’s model to reflect Select’s 82% stake in Concentra (CON) until the spinoff is completed later this year. The firm believes that the market is undervaluing Select’s RemainCo with the implied multiple of six-times EBITDA despite growth in the mid-single digits, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEM:
- Select Medical Announces Board Resignation and CEO Appointment
- Select Medical Holdings Corporation Announces Results For Its Second Quarter Ended June 30, 2024 and Cash Dividend
- Select Medical backs FY24 adjusted EPS view 1.96-$2.20, consensus $2.12
- Select Medical reports Q2 adjusted EPS 60c, consensus 61c
- Select Medical, Cedars-Sinai launch specialized spine care program